Acid-Degradable LNP Lipids for Rapid Endosomal mRNA Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
LNP/mRNA complexes face limitations such as low endosomal disruption rates, high toxicity, and tissue persistence, which restrict their medical applications and prevent them from effectively treating a wide range of diseases.
Innovation Solution
Development of acid-degradable lipids, specifically oxyanion azide-benzaldehyde acetals, that hydrolyze rapidly within endosomes, enabling the creation of RD-LNPs that efficiently deliver mRNA to target organs and cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If conventional acid-degradable linkers are used in LNPs, then the LNPs can be formulated and remain stable in blood, but they degrade too rapidly at pH 7.4 and cannot achieve rapid hydrolysis within endosomes
Solution Approach 1:
The patent changes the chemical parameters of the linker by introducing electron-donating groups (alkyl, alkoxy, amino groups) at specific positions relative to the acetal carbon. This modifies the electronic environment to achieve pH-dependent hydrolysis kinetics: stable at physiological pH 7.4 but rapidly hydrolyzing at endosomal pH 6.0-6.8, thereby resolving the contradiction between stability and rapid degradation
Solution Approach 2:
The patent applies local quality by positioning specific substituent groups at defined spatial locations relative to the acetal carbon (ortho, meta, para positions). This localized structural modification creates the desired pH-responsive behavior only at the target site (endosome) while maintaining overall LNP stability in circulation
2Quantity of substance
If LNP/mRNA complexes are administered to achieve therapeutic protein quantities, then sufficient mRNA delivery is required, but the low endosomal disruption rate prevents efficient cytoplasmic delivery
Solution Approach 1:
The patent incorporates acid-degradable lipids with specifically engineered linkers into the LNP structure beforehand. These linkers are designed to remain intact during circulation and cellular uptake, then spontaneously hydrolyze at endosomal pH to trigger membrane disruption and mRNA release, performing the disruptive action at the precise moment and location needed
3Productivity
If cationic and ionizable lipids are used in LNPs to enable mRNA delivery, then transfection efficiency is improved, but toxicity and tissue persistence increase
Solution Approach 1:
The patent extracts the problematic cationic/ionizable lipid components and replaces them with acid-degradable neutral lipids containing the pH-sensitive acetal linker. This substitution removes the source of chronic toxicity and persistence while retaining the ability to deliver mRNA, as the degradation products are non-toxic and rapidly cleared from tissues
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
RD-LNPs enhance mRNA delivery to organs like the liver, spleen, and brain, reduce toxicity, and allow for efficient transfection of hematopoietic stem/progenitor cells, expanding the therapeutic potential of LNPs.
Implementation Method 1
The rapid hydrolysis of the RD-LNPs should enable them to trigger endosomal disruption and release of mRNA into the cytoplasm before mRNA degradation in the lysosomes occurs
Implementation Method 2
The azido-acetal has the stability needed for performing multi-step organic reactions and should enable the synthesis of acid-degradable lipids in high yields and their incorporation into LNPs in aqueous environments. However, before administration, the azido-acetal is reduced to an amine via the addition of thiols. This reduction accelerates the azido-acetal's hydrolysis rate
Data Source
AI summary
Compounds comprising an oxyanion azide-benzaldehyde acetal acid-degradable lipid are incorporated in lipid nanoparticle (LNP) and used to transfect cells.